73.79
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $73.79, with a volume of 3.43M.
It is up +1.30% in the last 24 hours and down -2.46% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$72.84
Open:
$73.7
24h Volume:
3.43M
Relative Volume:
0.68
Market Cap:
$228.77B
Revenue:
$54.07B
Net Income/Loss:
$7.04B
P/E Ratio:
32.72
EPS:
2.255
Net Cash Flow:
$7.28B
1W Performance:
-1.52%
1M Performance:
-2.46%
6M Performance:
-4.93%
1Y Performance:
+8.92%
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
AZN
Astrazeneca PLC
|
73.79 | 228.77B | 54.07B | 7.04B | 7.28B | 2.255 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-13-25 | Upgrade | UBS | Neutral → Buy |
Feb-12-25 | Initiated | Morgan Stanley | Overweight |
Nov-20-24 | Upgrade | UBS | Sell → Neutral |
Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
May-30-24 | Initiated | Goldman | Buy |
Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
Jan-23-24 | Initiated | Morgan Stanley | Overweight |
Jan-16-24 | Resumed | UBS | Sell |
Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
Dec-18-23 | Initiated | HSBC Securities | Buy |
Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Jul-12-23 | Upgrade | UBS | Neutral → Buy |
Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Aug-29-22 | Upgrade | Argus | Hold → Buy |
Jun-14-22 | Downgrade | UBS | Buy → Neutral |
Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
Aug-12-21 | Resumed | JP Morgan | Overweight |
Apr-12-21 | Downgrade | Argus | Buy → Hold |
Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
Feb-25-21 | Upgrade | UBS | Neutral → Buy |
Jan-15-21 | Initiated | Deutsche Bank | Buy |
Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-30-20 | Upgrade | UBS | Sell → Neutral |
Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
Sep-29-20 | Initiated | Berenberg | Buy |
Nov-22-19 | Initiated | SVB Leerink | Outperform |
Oct-25-19 | Upgrade | Liberum | Hold → Buy |
Apr-02-19 | Downgrade | UBS | Neutral → Sell |
Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
Dec-11-18 | Resumed | Jefferies | Hold |
Oct-09-18 | Initiated | Guggenheim | Buy |
Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
Feb-05-18 | Reiterated | Bernstein | Outperform |
Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
J&J Passes AstraZeneca in Lung Cancer Drug Race — For Now - MSN
SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding - GlobeNewswire Inc.
AstraZeneca Pharma India to discontinue manufacturing, marketing of angina drug from April 1 - Medical Dialogues
AstraZeneca's Imfinzi gains additional indication for bladder cancer - Seeking Alpha
AstraZeneca (AZN) Gains FDA Approval for New Imfinzi Indication - GuruFocus.com
Is AstraZeneca (AZN) the Best ADR Stock to Buy According to Hedge Funds? - Yahoo Finance
AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch
AstraZeneca Sues Consultancy For £32M Over HQ Defects - Law360
Goldman Sachs maintains AstraZeneca stock with $98 target By Investing.com - Investing.com UK
Goldman Sachs lifts AstraZeneca stock target, sees growth By Investing.com - Investing.com UK
AstraZeneca Fights Generic Diabetes Drug Launch - Law360
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga
Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet - Yahoo Finance
Berenberg Keeps AstraZeneca at Buy on Pipeline Potential - Marketscreener.com
Del. Justices Back Axing Suit Over $3B AstraZeneca Viela Sale - Law360
J&J passes AstraZeneca in lung cancer drug race — for now - Crain's New York Business
J&J’s Rybrevant-Lazcluze Combo Tops AstraZeneca’s Drug in EGFR Lung CancerJohnson & Johnson (NYSE:JNJ) - Benzinga
J&J Passes AstraZeneca in Blockbuster Cancer Race — For Now - Bloomberg
AstraZeneca's Win in Shareholder Suit Over Viela Sale Affirmed - Bloomberg Law
China on track to outpace Europe in pharmaceutical innovation, says AstraZeneca CEO By Investing.com - Investing.com South Africa
China on track to outpace Europe in pharmaceutical innovation, says AstraZeneca CEO - Investing.com India
Europe Rapidly Falling Behind China in Pharma, AstraZeneca CEO Warns - Bloomberg
Whittier Trust Co. Boosts Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Astrazeneca invests in China: $8B in deals, $2.5B in R&D center - BioWorld Online
Astrazeneca Says Tagrisso Shows Improved Overall Survival Trend In Laura Phase 3 Trial - Marketscreener.com
AstraZeneca Seeks to Move Past China Probe With R&D Hub - Bloomberg
AstraZeneca seeks to move past China probe with Beijing R&D hub - The Edge Malaysia
AstraZeneca PLC ADR underperforms Monday when compared to competitors - MarketWatch
Assemblin to upgrade AstraZeneca’s Gärtuna plant in Sweden - Yahoo Finance
AstraZeneca and GKS shares have legs, but the weight loss titans will dominate, says investment bank - Proactive Investors UK
Prediction: 12 months from now, AstraZeneca’s share price could be… - Yahoo Finance UK
AstraZeneca to invest $2.5bn in R&D centre in China - Pharmaceutical Technology
Assemblin Caverion Group Unit to Upgrade AstraZeneca's Swedish Plant -March 24, 2025 at 03:37 am EDT - Marketscreener.com
Top global stories of the week: AstraZeneca, BYD, SoftBank among notable names - Seeking Alpha
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca Expands Emphasis On China, Already A Key Market - News & Insights
AstraZeneca PLC ADR falls Friday, underperforms market - MarketWatch
Sector Update: Health Care Stocks Retreat Late Afternoon -March 21, 2025 at 03:50 pm EDT - Marketscreener.com
AstraZeneca to invest $2.5bn in China after snub for UK plant - The Times
AstraZeneca To Invest $2.5B In China Research Hub - Law360
Sector Update: Health Care Stocks Fall in Afternoon Trading -March 21, 2025 at 01:50 pm EDT - Marketscreener.com
Sector Update: Health Care -March 21, 2025 at 01:39 pm EDT - Marketscreener.com
Going in vivo: AstraZeneca acquires EsoBiotec in potential $1bn deal - BioXconomy
AstraZeneca deepens China investment; Editas loses CFO to Dyne - BioPharma Dive
HBM Holdings To Issue To Astrazeneca Holdings Subscription Shares -March 21, 2025 at 11:28 am EDT - Marketscreener.com
Kangtai Biological Products To Establish JV With AstraZeneca -March 21, 2025 at 10:40 am EDT - Marketscreener.com
AstraZeneca to invest £2bn in Beijing amid China investigation - Yahoo Finance
Micron, Johnson & Johnson, AstraZeneca: Top Stocks - Yahoo Finance
Astrazeneca enters multispecific antibody collaborations with CEPI, Harbour Biomed - BioWorld Online
AstraZeneca to make a $2.5B investment in China (AZN:NASDAQ) - Seeking Alpha
AstraZeneca invests US$2.5 bil in Beijing hub amid probe - The Edge Malaysia
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):